


## PHARMACEUTICAL 2020



## Iterum Therapeutics plc Rank 344 of 362





## PHARMACEUTICAL 2020



## Iterum Therapeutics plc Rank 344 of 362

The relative strengths and weaknesses of Iterum Therapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Iterum Therapeutics plc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 176% points. The greatest weakness of Iterum Therapeutics plc is the variable Research and Development, reducing the Economic Capital Ratio by 632% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,151%, being 849% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	11,718
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	36,986
Liabilities, Non-Current	15,003
Other Assets	13,461
Other Compr. Net Income	0
Other Expenses	444
Other Liabilities	0
Other Net Income	-665
Property and Equipment	572
Research and Development	90,774
Revenues	37
Selling, General and Administrative Expense	11,284

Output Variable	Value in 1000 USD
Assets	25,751
Liabilities	51,989
Expenses	102,502
Stockholders Equity	-26,238
Net Income	-103,130
Comprehensive Net Income	-103,130
Economic Capital Ratio	-1,151%